Indivior (INDV) Competitors

$36.76 -1.07 (-2.83%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$36.35 -0.41 (-1.10%)

As of 05/15/2026 07:04 PM Eastern

INDV vs. GMAB, ASND, RGC, SMMT, and BBIO

Should you buy Indivior stock or one of its competitors? MarketBeat compares Indivior with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Indivior include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Regencell Bioscience (RGC), Summit Therapeutics (SMMT), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.

How does Indivior compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Genmab A/S has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.45	$963M	$1.32	20.11
Indivior	$1.24B	3.62	$210M	$1.95	18.85

Genmab A/S has a net margin of 21.05% compared to Indivior's net margin of 19.44%. Genmab A/S's return on equity of 15.34% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Indivior	19.44%	-219.26%	29.40%

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genmab A/S has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Indivior has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Genmab A/S presently has a consensus price target of $39.07, indicating a potential upside of 47.22%. Indivior has a consensus price target of $39.33, indicating a potential upside of 7.00%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Genmab A/S had 2 more articles in the media than Indivior. MarketBeat recorded 6 mentions for Genmab A/S and 4 mentions for Indivior. Indivior's average media sentiment score of 1.25 beat Genmab A/S's score of 0.60 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Indivior on 11 of the 17 factors compared between the two stocks.

How does Indivior compare to Ascendis Pharma A/S?

Indivior (NASDAQ:INDV) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Indivior currently has a consensus price target of $39.33, suggesting a potential upside of 7.00%. Ascendis Pharma A/S has a consensus price target of $291.78, suggesting a potential upside of 21.32%. Given Ascendis Pharma A/S's higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95

60.3% of Indivior shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Ascendis Pharma A/S has a net margin of 57.87% compared to Indivior's net margin of 19.44%. Ascendis Pharma A/S's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Indivior has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Indivior. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 4 mentions for Indivior. Indivior's average media sentiment score of 1.25 beat Ascendis Pharma A/S's score of 0.63 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior has higher revenue and earnings than Ascendis Pharma A/S. Indivior is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.62	$210M	$1.95	18.85
Ascendis Pharma A/S	$865.78M	17.33	-$258M	$8.67	27.74

Summary

Ascendis Pharma A/S beats Indivior on 9 of the 16 factors compared between the two stocks.

How does Indivior compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Indivior (NASDAQ:INDV) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Regencell Bioscience had 17 more articles in the media than Indivior. MarketBeat recorded 21 mentions for Regencell Bioscience and 4 mentions for Indivior. Indivior's average media sentiment score of 1.25 beat Regencell Bioscience's score of 0.08 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Indivior	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Indivior	$1.24B	3.62	$210M	$1.95	18.85

Indivior has a consensus target price of $39.33, suggesting a potential upside of 7.00%. Given Indivior's stronger consensus rating and higher possible upside, analysts clearly believe Indivior is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Indivior has a net margin of 19.44% compared to Regencell Bioscience's net margin of 0.00%. Regencell Bioscience's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Indivior	19.44%	-219.26%	29.40%

Regencell Bioscience has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, Indivior has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Summary

Indivior beats Regencell Bioscience on 10 of the 14 factors compared between the two stocks.

How does Indivior compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Summit Therapeutics has a beta of -1.25, suggesting that its share price is 225% less volatile than the broader market. Comparatively, Indivior has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Indivior has a net margin of 19.44% compared to Summit Therapeutics' net margin of 0.00%. Indivior's return on equity of -219.26% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Indivior	19.44%	-219.26%	29.40%

Summit Therapeutics presently has a consensus target price of $27.58, suggesting a potential upside of 63.51%. Indivior has a consensus target price of $39.33, suggesting a potential upside of 7.00%. Given Summit Therapeutics' higher probable upside, equities analysts clearly believe Summit Therapeutics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.50
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Indivior has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Indivior	$1.24B	3.62	$210M	$1.95	18.85

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Indivior had 2 more articles in the media than Summit Therapeutics. MarketBeat recorded 4 mentions for Indivior and 2 mentions for Summit Therapeutics. Indivior's average media sentiment score of 1.25 beat Summit Therapeutics' score of 0.89 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Indivior beats Summit Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Indivior compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

BridgeBio Pharma has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Indivior has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Indivior has a net margin of 19.44% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Indivior	19.44%	-219.26%	29.40%

Indivior has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	25.80	-$724.93M	-$3.74	N/A
Indivior	$1.24B	3.62	$210M	$1.95	18.85

BridgeBio Pharma currently has a consensus price target of $88.19, suggesting a potential upside of 33.36%. Indivior has a consensus price target of $39.33, suggesting a potential upside of 7.00%. Given BridgeBio Pharma's higher possible upside, research analysts clearly believe BridgeBio Pharma is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.92
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, BridgeBio Pharma had 28 more articles in the media than Indivior. MarketBeat recorded 32 mentions for BridgeBio Pharma and 4 mentions for Indivior. Indivior's average media sentiment score of 1.25 beat BridgeBio Pharma's score of 0.73 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	8 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Indivior beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

Get Indivior News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDV vs. The Competition

Export

Metric	Indivior	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.48B	$3.00B	$6.38B	$12.30B
Dividend Yield	N/A	1.97%	2.81%	5.26%
P/E Ratio	18.85	17.57	20.66	25.27
Price / Sales	3.62	269.52	552.79	74.65
Price / Cash	13.52	57.31	42.43	54.86
Price / Book	-31.15	4.33	9.87	6.90
Net Income	$210M	$72.19M	$3.57B	$334.66M
7 Day Performance	-6.94%	-3.06%	0.23%	0.12%
1 Month Performance	12.42%	-5.08%	-2.54%	-0.18%
1 Year Performance	224.16%	36.79%	33.54%	30.62%

Indivior Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDV Indivior	3.9089 of 5 stars	$36.76 -2.8%	$39.33 +7.0%	+224.2%	$4.48B	$1.24B	18.85	1,051	Positive News
GMAB Genmab A/S	4.1442 of 5 stars	$26.18 -0.9%	$39.07 +49.2%	+33.5%	$16.48B	$3.90B	19.83	3,029
ASND Ascendis Pharma A/S	3.7026 of 5 stars	$238.67 +0.0%	$291.50 +22.1%	+52.6%	$14.89B	$814.57M	27.53	1,189	Positive News Analyst Forecast Insider Trade
RGC Regencell Bioscience	0.3574 of 5 stars	$27.33 -6.7%	N/A	N/A	$14.48B	N/A	N/A	10	Earnings Report
SMMT Summit Therapeutics	3.0155 of 5 stars	$18.66 +3.2%	$27.58 +47.8%	-29.3%	$14.03B	N/A	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDV) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indivior (INDV) Competitors

INDV vs. GMAB, ASND, RGC, SMMT, and BBIO

How does Indivior compare to Genmab A/S?

Summary

How does Indivior compare to Ascendis Pharma A/S?

Summary

How does Indivior compare to Regencell Bioscience?

Summary

How does Indivior compare to Summit Therapeutics?

Summary

How does Indivior compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indivior (INDV) Competitors

INDV vs. GMAB, ASND, RGC, SMMT, and BBIO

How does Indivior compare to Genmab A/S?

Which has preferable valuation and earnings, GMAB or INDV?

Is GMAB or INDV more profitable?

Do institutionals and insiders believe in GMAB or INDV?

Which has more risk and volatility, GMAB or INDV?

Do analysts rate GMAB or INDV?

Does the media refer more to GMAB or INDV?

Summary

How does Indivior compare to Ascendis Pharma A/S?

Do analysts rate INDV or ASND?

Do insiders and institutionals have more ownership in INDV or ASND?

Is INDV or ASND more profitable?

Which has more risk & volatility, INDV or ASND?

Does the media favor INDV or ASND?

Which has preferable valuation & earnings, INDV or ASND?

Summary

How does Indivior compare to Regencell Bioscience?

Does the media refer more to RGC or INDV?

Which has better valuation and earnings, RGC or INDV?

Do analysts rate RGC or INDV?

Do institutionals and insiders have more ownership in RGC or INDV?

Is RGC or INDV more profitable?

Which has more risk and volatility, RGC or INDV?

Summary

How does Indivior compare to Summit Therapeutics?

Which has more volatility & risk, SMMT or INDV?

Is SMMT or INDV more profitable?

Do analysts recommend SMMT or INDV?

Which has preferable valuation & earnings, SMMT or INDV?

Do insiders & institutionals have more ownership in SMMT or INDV?

Does the media refer more to SMMT or INDV?

Summary

How does Indivior compare to BridgeBio Pharma?

Which has more volatility & risk, BBIO or INDV?

Is BBIO or INDV more profitable?

Which has higher earnings & valuation, BBIO or INDV?

Do analysts rate BBIO or INDV?

Do institutionals and insiders hold more shares of BBIO or INDV?

Does the media favor BBIO or INDV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools